Acceleron Pharma Inc

Acceleron Pharma — Investor Day (June 2021)

139 slides from Acceleron Pharma's investor day presentation, Jun 22, 2021

  1. Slide 1: Research & Development Day 2021

    R E S E A R C H & D E V E L O P M E N T D A Y 2 0 2 1 J U N E 2 2 , 2 0 2 1

  2. Slide 2: Forward-Looking Statements

    Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE INCLUDED IN THE FORWARD-LOOKING STATEMENTS DUE TO VARIOUS THE FORWARD-LOOKING STATEMENTS CONTAINED IN

  3. Slide 3: Welcome and R&D Day Agenda

    Welcome and R&D Day Agenda AC CE LERON VISION & S TRATEGY Our Approach to Research & Development 8:00 – 8:25 AM WHO GROUP 1 & 2 PUL MON ARY HYPER TENSION 8:25 – 10:00 AM S YS TEMIC SC LEROSIS- ASSOC IATED INTERS TITIAL LUNG DISE ASE 10:00 – 10:35 AM CL OSING R EMARKS AND Q&A SESSION10:35 – 11:00 AM

  4. Slide 4: Habib Dable, President & CEO

    — 7 >= ACCELERON ==" ACCELERO HABIB DABLE, PRESIDENT & CEO

  5. Slide 5: Our Mission

    O UR MI SSI ON

  6. Slide 6: A Leader in Understanding the TGF-beta Superfamily

    A Leader in Understanding the TGF-beta Superfamily More Than 18 Years of Focus The TGF-beta superfamily influences many biological processes, including cellular: Growth Differentiation Repair

  7. Slide 7: Building a Global Acceleron for 2021 and Beyond

    Building a Global Acceleron for 2021 and Beyond ACCELERON PHARMA RARE PULMONARY DISEASE HEMATOLOGY OUR PEOPLE “ACCELERATORS” TGF-BETA SUPERFAMILY RESEARCH BUSINESS DEVELOPMENT

  8. Slide 8: Our Vision for Sotatercept in PAH

    Our Vision for Sotatercept in Pulmonary Arterial Hypertension (PAH) BACKBONE THERAPY IN PAH

  9. Slide 9: Expanding Our Vision for Sotatercept in Pulmonary Hypertension

    Expanding our Vision for Sotatercept in Pulmonary Hypertension GROUP 1 Pulmonary Arterial Hypertension GROUP 2 Left Heart Disease GROUP 3 Interstitial Lung Disease TBD Program Status Phase 3 Development Underway Phase 2 Proof of Concept Trial Planned Scientific and Preclinical Evaluation Ongoing Cpc

  10. Slide 10: ACE-1334 Adds Second Program to Build Rare Pulmonary Franchise

    ACE-1334 Adds Second Program to Build Franchise in Rare Pulmonary sotatercept PULMONARY ACE-1334 >50,000 patients in the US and EU + WHO Group 1 WHO Group 2

  11. Slide 11: Future Royalties from REBLOZYL Provide a Strong Foundation for Growth

    Future Royalties from REBLOZYL® Provide a Strong Foundation for Growth B R I S T O L A N D A C C E L E R O N ’ S E S T I M AT E D A N N U A L P E A K S A L E S P O T E N T I A L $4 Billion+ 2029 non risk-adjusted peak sales estimate of $4 billion+ for REBLOZYL assumes success in current and potentia

  12. Slide 12: Rare Pulmonary Leader

    RARE PULMONARY LEADER RESEARCH BUSINESS DEVELOPMENT S O T A T E R C E P T • • A C E – 1 3 3 4 • Maximize REBLOZYL opportunity in collaboration with Bristol Myers Squibb Significant Growth Potential from Current Programs Along with Organic and Inorganic R&D N E W D I S E A S E A R E A S R A R E P U L

  13. Slide 13: Jay Backstrom, Head of Research & Development

    J AY B AC KS TR OM , MD , M PH H E A D O F R E S E A R C H & D E V E L O P M E N T

  14. Slide 14: Our Science: Understanding the TGF-beta Superfamily Biology

    Our Science: Understanding the TGF-beta Superfamily Biology Type 1 Type 2 Activin/GDF LigandsBMP/GDF Ligands Type 2Type 1 TGF-β Ligands Type 1 Type 2 Ligands Receptors

  15. Slide 15: Versatility of the TGF-beta Superfamily Cellular Signaling Pathways

    Versatility of the TGF-beta Superfamily Cellular Signaling Pathways    Tamayo E, et al. Int. J. Mol. Sci. 2018, 19(12), 3928

  16. Slide 16: Our Technology: Fusion Protein Traps

    Our Technology: Engaging the TGF-beta Superfamily Biology with Fusion Protein Traps Acceleron’s Fusion Proteins

  17. Slide 17: Our Approach: From Bench to Bedside and Back

    Our Approach: From Bench to Bedside and Back      

  18. Slide 18: Luspatercept: Translation from Preclinical to Clinical Results

    Luspatercept: Robust Translation from Preclinical to Clinical Results in Anemia Associated with Rare Blood Disorders RAP-536 | • luspatercept | •

  19. Slide 19: Our Success: REBLOZYL

    Our Success: REBLOZYL® The First and Only Approved Erythroid Maturation Agent +

  20. Slide 20: Sotatercept: Translation from Preclinical to Clinical Results in PAH

    Sotatercept: Robust Translation from Preclinical to Clinical Results in PAH RAP-011 | • sotatercept | • N Engl J Med

  21. Slide 21: Significant Progress in Advancing Sotatercept in PH

    Significant Progress in Advancing Sotatercept in Pulmonary Hypertension PULSAR SPECTRA 2017 2018 2019 2020 2021 Acceleron BREAKTHROUGH THERAPY DESIGNATION EMA PRI ME Z E N I T H

  22. Slide 22: Scientific Rationale to Expand Sotatercept into WHO Group 2 PH and ACE-1334 in SSc-ILD

    Strong Scientific Rationale and Preclinical Results to Expand Sotatercept into WHO Group 2 PH and Develop ACE-1334 in SSc-ILD • • • • P H A S E 2 T R I A L • • • A C E - 1 3 3 4 P H A S E 1 b / P H A S E 2 T R I A L

  23. Slide 23: Building a Leading Rare Pulmonary Pipeline

    Building a Leading Rare Pulmonary Pipeline Sotatercept PHASE 1 PHASE 2 PHASE 3 ACE-1334

  24. Slide 24: Sotatercept in Pulmonary Hypertension

    S O TATER C EPT IN P UL M ON AR Y HY P ER TEN SI ON Sotatercept is an investigational therapy that is not approved for any use in any country.

  25. Slide 25: PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision

    PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision ZENITH Patient Population Newly diagnosed stable double combination background therapy Stable background therapy (mono, double, or triple) Stable maximum background therapy

  26. Slide 26: Our Guest Speakers

    Our Guest Speakers M A R C H U M B E R T , M D , P H D * V A L L E R I E M C L A U G H L I N , M D * M A R D I G O M B E R G - M A I T L A N D , M D , M S c * *Drs. Gomberg, Humbert, and McLaughlin are investigators in multiple ongoing and planned Acceleron-sponsored clinical trials and are paid con

  27. Slide 27: Marc Humbert, MD, PhD

    Professor of Respiratory Medicine at the Université Paris-Saclay in Le Kremlin-Bicêtre, France; Director of the Department of Respiratory and Intensive Care Medicine, French Pulmonary Hypertension Reference Centre, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France *Dr. Humbert is an inv

  28. Slide 28: PAH: A Disease of Cellular Proliferation and Vascular Remodeling

    Pulmonary Arterial Hypertension: A Disease of Cellular Proliferation and Vascular Remodeling1,2 Definition: chronic pre-capillary pulmonary hypertension Cause: progressive structural remodeling of the pulmonary arteries Consequence: right heart failure and death Normal PAH J Signal Transduct Eur Res

  29. Slide 29: Pulmonary Hypertension WHO Groups

    Pulmonary Hypertension WHO Groups Eur Respir J. Circ Cardiovasc Qual Outcomes Group 1: PAH Group 2: Left Heart Disease Group 3: Lung Disease Group 4: CTEPH Group 5: Multifactorial Idiopathic Heritable Drug and Toxin Induced Associated With CTD, HIV, Portal Hypertension, CHD, or Schistosomiasis PVOD/

  30. Slide 30: Current Approved Therapies Target Three Pathways in PAH

    Current Approved Therapies Target Three Pathways of Endothelial Dysfunction in PAH

  31. Slide 31: Key Measures for Risk Stratification From Registries

    Summary of Key Measures for Risk Stratification From Registries   noninvasive endpoints (FC, 6MWD, and BNP/NT-proBNP) REVEAL 2.02 SPAHR3 COMPERA4 FPHR5 FPHR 5 (noninvasive) Eur Respir J Chest Eur Heart J Eur Respir J Eur Respir J

  32. Slide 32: PAH Treatment Algorithm

    Pulmonary Arterial Hypertension Treatment Algorithm

  33. Slide 33: Goals of Current Therapeutic Approaches

    Goals of Current Therapeutic Approaches Include Delay of Functional Impairment and Improved Outcomes1,2 Time Fu nc ti on al C ap ac it y Ultimate goals: no functional impairment and outcome improvement Eur Respir Rev Eur Heart J Eur Respir Rev

  34. Slide 34: How to Improve Patient Outcomes?

    How to Improve Patient Outcomes?  

  35. Slide 35: Targeting Novel Pathways in PAH

    Targeting Novel Pathways in PAH • Pulmonary artery endothelial cell dysfunction is a major abnormality identified in PAH • Strong translational research has identified a large number of novel targets in recent years • A major challenge will be to prioritize drug discovery and development Inflammatio

  36. Slide 36: Identifying the Role of BMPR2 in Pulmonary Hypertension

    Identifying the Role of BMPR2 in Pulmonary Hypertension • The BMP signaling pathway is defective in patients with familial primary pulmonary hypertension1 • Additional evidence of the role of BMP signaling pathway in PH, demonstrating reduced BMPR-II expression in primary pulmonary hypertension3 • F

  37. Slide 37: Pulmonary Arterial Hypertension and Sotatercept

    Pulmonary Arterial Hypertension and Sotatercept Pulmonary Arterial Hypertension Sotatercept et al. Circ Res , et al. N Engl J Med et al. Haematologica. et al. Sci Transl Med.

  38. Slide 38: Preclinical Sotatercept Research

    Preclinical Sotatercept Research • Treatment with sotatercept in preclinical experiments improved: – Hemodynamics – Right ventricular (RV) hypertrophy – RV function – Arteriolar remodeling • Sotatercept has been demonstrated preclinically to act via a mechanism linked to rebalancing pro- proliferati

  39. Slide 39: Vallerie McLaughlin, MD

    Professor of Cardiovascular Medicine; Director of the Pulmonary Hypertension Program University of Michigan *Dr. McLaughlin is an investigator in multiple ongoing and planned Acceleron- sponsored clinical trials and a paid consultant to Acceleron. VAL L ER I E M C L AU GH L IN , M D*

  40. Slide 40: PULSAR Trial Design Schema

    PULSAR Trial Design Schema A Phase 2, double-blind, randomized, placebo-controlled, parallel-group study K E Y I N C L U S I O N C R I T E R I A • • • • • – Randomization 3:3:4 (24 weeks) (ongoing) Trial currently in open-label extension phase 1:1

  41. Slide 41: PULSAR Baseline Characteristics

    PULSAR Baseline Characteristics (N=106) 3% Corrected congenital shunt-associated 7% Drug or toxin induced 16% Heritable 17% CTD- associated 58% Idiopathic PAH classification N Engl J Med Standard-of-care PAH therapy 9% Monotherapy 35% Double therapy 56% Triple therapy 53% FC II; 47% FC III Pulmonary

  42. Slide 42: PULSAR 24-Week Primary and Key Secondary Endpoints

    PULSAR 24-Week Primary and Key Secondary Endpoints Primary: Pulmonary Vascular Resistance Key Secondary: 6-Minute Walk Distance Change in 6MWD from baseline to Week 24 (LS mean ± SE) Placebo-corrected LS mean difference of 25 m (SE=11.1) at Week 24 (P=0.03*) N Engl J Med

  43. Slide 43: PULSAR 24-Week Exploratory Analysis: Multicomponent Improvement

    M E E T I N G A L L T H R E E C R I T E R I A : PULSAR 24-Week Exploratory Analysis: Multicomponent Improvement 3% 38% 0% 20% 40% 60% Placebo + SOC (n=32) Sotatercept + SOC all doses (n=74) P a ti e n ts WHO FC: improvement or maintenance of FC II NT-proBNP: ≥30% improvement 6MWD: ≥30-m improvement

  44. Slide 44: ATS 2021: PULSAR Open-label Extension 48-week Interim Results

    ATS 2021: PULSAR Study Open-label Extension 48-week Interim Results NT-proBNP (pg/mL) n=35 n=29 6MWD (m) Continuing 0.7 mg/kg + SOC Continuing 0.3 mg/kg + SOC Placebo + SOC / 0.7 mg/kg + SOC Placebo + SOC / 0.3 mg/kg + SOC n=29 n=27 n=14 n=13 n=15 n=12 n=42 n=40 n=32 n=32 n=15 n=15 n=15 n=14 n=34 n=

  45. Slide 45: PULSAR Safety 24-week and 48-week OLE Summary

    PULSAR Safety 24-week and 48-week OLE Summary TEAEs during the OLE period only, n (%) Continuing 0.3 mg/kg + SOC (n=31) Continuing 0.7 mg/kg + SOC (n=36) Placebo + SOC / 0.3 mg/kg + SOC (n=15) Placebo + SOC / 0.7 mg/kg + SOC (n=15) TEAEs Serious TEAEs Serious related TEAEs TEAEs leading to treatment

  46. Slide 46: STELLAR Phase 3 Study

    A Phase 3, randomized, double-blind, placebo- controlled study to compare the efficacy and safety of sotatercept versus placebo when added to background PAH therapy for the treatment of PAH Sotatercept is an investigational therapy that is not approved for any use in any country.

  47. Slide 47: Key Inclusion Criteria for PULSAR Relative to STELLAR

    Key Inclusion Criteria for PULSAR Relative to STELLAR Phase 3 Trial Key Inclusion Criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class II or III • Baseline RHC with PVR ≥5 Wood units • Baseline 6-minute walk distance 150-500 m • Stable treatment with background therapies, includi

  48. Slide 48: STELLAR Phase 3 Trial Design Schema

    STELLAR Phase 3 Trial Design Schema Randomization 1:1 N=284 Primary Endpoint Analysis ENROLLING

  49. Slide 49: Primary Endpoint

    Primary Endpoint Primary Endpoint • Change from baseline in 6-minute walk distance at week 24

  50. Slide 50: Secondary Endpoints

    Secondary Endpoints Secondary Endpoints • Multicomponent improvement endpoint measured by the proportion of participants achieving all of the following at 24 weeks as compared to baseline: Improvement in 6MWD (increase ≥ 30 m) Improvement in NT-proBNP (decrease in NT-proBNP ≥ 30% or maintenance/achi

  51. Slide 51: HYPERION Phase 3 Study

    A Phase 3, randomized, double-blind, placebo- controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- or high-risk PAH patients. Sotatercept is an investigational therapy that is not approved for any use in any country.

  52. Slide 52: Enrichment Benefits of Risk Algorithms for PAH Clinical Trials

    Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials HYPERION Trial Enriched for Risk Scores Measurements and Main Results: Conclusions:

  53. Slide 53: REVEAL Lite Risk Score

    REVEAL Lite 2 Risk Score REVEAL 2 B. REVEAL Lite 2 Lite = RISK SCORE Survival Probability 1.0 0.8 0.6 0.4 0.2 Low (n= 960, [events = 123); 83, [events = 231]); HR (95% Cl 2.267 (1.822, 2.822) P-value: <.0001 686, [events = 365]); HR (95% Cl 6.355 (5.175, 7.804) P-value: <,0001 T T T T T T T T T 12 1

  54. Slide 54: Treatment Algorithm From 6th World Symposium on PH

    Treatment Algorithm From 6th World Symposium on Pulmonary Hypertension for Treated Patients1 Structured follow-up Patient already on treatment Reassess after 3 to 6 months of treatment Consider referral for lung transplantation Intermediate or high risk* Triple sequential combination†Low risk* After

  55. Slide 55: Case Studies

    Case Studies Case 1   Case 2     

  56. Slide 56: Case Studies (Continued): Right Heart Catheterization Hemodynamics

    Case Studies (Continued…) Right Heart Catheterization HemodynamicsHemodynamics Case 1 Case 2

  57. Slide 57: Case Studies (Continued): Treatment Course

    Treatment Course      Case Studies (Continued…)

  58. Slide 58: Case Studies (Continued): Follow-up

    Case Studies (Continued…) Follow-up Case 1       Case 2      

  59. Slide 59: HYPERION Phase 3 Trial Inclusion Criteria

    HYPERION Phase 3 Trial Inclusion Criteria Key Inclusion Criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class II or III • Up to 6 months from diagnosis • Intermediate- and high-risk scores (REVEAL Lite 2) • Baseline RHC with PVR ≥4 Wood units • Baseline 6-minute walk distance ≥150

  60. Slide 60: HYPERION Phase 3 Trial Design Schema

    HYPERION Phase 3 Trial Design Schema Randomization 1:1 (up to 4 weeks) N = 662 Primary Endpoint Analysis

  61. Slide 61: HYPERION Primary Endpoint

    HYPERION Primary Endpoint Time to Clinical Worsening, defined as the first confirmed morbidity event or death. The events that will comprise this endpoint include the following: • All-cause death • Non-planned PAH-related hospitalization of ≥24 hours in duration • Atrial septostomy • Lung transplant

  62. Slide 62: HYPERION Secondary Endpoints

    HYPERION Secondary Endpoints Secondary Endpoints • Multicomponent improvement endpoint measured by the proportion of participants achieving all of the following at 24 weeks as compared to baseline: Improvement in 6MWD (increase ≥ 30 m) Improvement in NT-proBNP (decrease in NT-proBNP ≥ 30% or mainten

  63. Slide 63: Marc Humbert, MD, PhD

    Professor of Respiratory Medicine at the Université Paris-Saclay in Le Kremlin-Bicêtre, France; Director of the Department of Respiratory and Intensive Care Medicine, French Pulmonary Hypertension Reference Centre, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France *Dr. Humbert is an inv

  64. Slide 64: ZENITH Phase 3 Study

    A Phase 3, randomized, double-blind, placebo- controlled study to evaluate sotatercept when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours, in participants with WHO FC IV PAH or

  65. Slide 65: PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision

    PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision ZENITH Patient Population Newly diagnosed stable double combination background therapy Stable background therapy (mono, double, or triple) Stable maximum background therapy

  66. Slide 66: PAH Functional Class Assessments

    WHO: World Health Organization PAH Functional Class Assessments NYHA FUNCTIONAL CLASS WHO FUNCTIONAL CLASS DESCRIPTIONS NYHA: New York Heart Association

  67. Slide 67: Survival By NYHA Functional Class

    Survival By New York Heart Association (NYHA) Functional Class Survival (%) Time (months) 0 362412 NYHA I/II NYHA III NYHA IV 0 60 100 80 40 20 Survival (%) # at risk: NYHA I/II NYHA III NYHA IV 12 37 7 15 48 6 19 70 9 23 79 11 24 86 10 26 88 13 27 89 17

  68. Slide 68: A PAH Patient in Need of a Fourth Pathway

    A PAH Patient in Need of a Fourth Pathway    BMPR2             

  69. Slide 69: Baseline and Initial Management

    Baseline REVEAL Lite 2 NYHA functional class IV 2 6-MWD, m 100 1 Systolic blood pressure, mmHg 100 1 Heart rate, bpm 100 1 NT-proBNP, ng/L 3000 2 Renal failure No 0 RAP, mm Hg CI, L/min/m2 SvO2, % 19 1.6 50 - REVEAL Lite 2 = 13 (2 + 1 + 1 + 1 + 2 + 6) Status: High risk Idiopathic PAH IV diuretics IV

  70. Slide 70: Evaluation at 6 Months

    Baseline 6 months NYHA functional class IV III 6-MWD, m 100 300 Systolic blood pressure, mmHg 100 100 Heart rate, bpm 100 100 NT-pro BNP, ng/L 3000 1400 Renal failure No No RAP, mm Hg CI, L/min/m2 SvO2, % 19 1.6 50 11 2.2 58 REVEAL Lite 2 = 11 (1 + 0 + 1 + 1 + 2 + 6) Status: High risk idiopathic PAH

  71. Slide 71: ZENITH Phase 3 Trial Inclusion Criteria

    ZENITH Phase 3 Trial Inclusion Criteria ZENITH Key Inclusion Criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class III or IV • Reveal Lite 2 Risk Score of ≥ 10 • Baseline RHC with PVR ≥5 Wood units • Stable on maximum tolerated background PAH therapy

  72. Slide 72: ZENITH Phase 3 Trial Design Schema

    ZENITH Phase 3 Trial Design Schema ZENITH Randomization 1:1 (up to 4 weeks) N = up to 166 Primary Endpoint Analysis

  73. Slide 73: Primary and Key Secondary Endpoints

    Primary and Key Secondary Endpoints ZENITH Primary Endpoint • Time to all-cause death or time to PAH-related hospitalization of ≥ 24 hours Key Secondary Endpoints • Overall survival • Transplant- and ECMO-free survival

  74. Slide 74: Additional Secondary Endpoints and Analyses

    Additional Secondary Endpoints and Analyses ZENITH • Change from baseline in REVEAL Lite 2 risk score • Proportion of participants achieving a low or intermediate (≤7) REVEAL Lite 2 risk score • Change from baseline in NT-proBNP • Change from baseline in PVR • Change from baseline in mean pulmonary

  75. Slide 75: Mardi Gomberg-Maitland, MD, MSc

    Professor of Medicine and Director of the Pulmonary Hypertension Program at The George Washington University Hospital *Dr. Gomberg is an investigator in multiple ongoing and planned Acceleron- sponsored clinical trials and a paid consultant to Acceleron. M A R D I G O M B E R G - M A I T L A N D , M

  76. Slide 76: Clinical Classification of Pulmonary Hypertension: WHO Groups

    Clinical Classification of Pulmonary Hypertension: WHO GROUPS 1. Pulmonary arterial hypertension 2. Pulmonary hypertension due to left heart disease 3. Pulmonary hypertension due to lung diseases and/or hypoxia 4. Pulmonary hypertension due to pulmonary artery obstructions 5. Pulmonary hypertension

  77. Slide 77: Global Perspective: PH Left Heart Disease Worldwide

    Global Perspective – PH: 40-50% PH Left Heart Disease Worldwide Lancet Respir Med

  78. Slide 78: What are the Causes of Group 2 PH

    What are the Causes of Group 2 PH  Chronic systolic LV heart failure: the heart squeeze is down= Heart Failure Reduced Ejection Fraction (HFrEF)- dilated LV  Chronic diastolic LV heart failure: the heart relaxes poorly= Heart failure Preserved Ejection Fraction (HFpEF)- thick LV  Heart failure fr

  79. Slide 79: Group 2: Left Heart Disease

    Eur Respir J. Group 2: Left Heart Disease Heart Failure With Preserved Ejection Fraction (HFpEF) Heart Failure With Reduced Ejection Fraction (HFrEF) Valvular Heart Disease Dysfunction/Congenital/ Acquired LH Inflow/ Outflow Tract          Prognosis Symptoms Cause / Risk Factors Description

  80. Slide 80: Combined Pre-post Capillary PH: 2 Hits

    LV Injury and Dysfunction LVEDP, PAWP, MR, Neurohormones, Cytokines Pulmonary Endothelial Cell Dysfunction: ET, NO & cGMP Pulmonary Vasoconstriction/Pulmonary Vascular Remodeling Pulmonary Hypertension RV Remodeling and Failure Morbidity and Mortality Pulmonary Venous Hypertension Pulmonary Arterial

  81. Slide 81: High Mortality with HFpEF-PH

    High Mortality with HFpEF-PH: As Bad As End Stage Lung Cancer 340 WHO Group II PH patients with any follow-up from baseline diagnosis. 2 year survival from baseline diagnosis by score Worse than Group 1 PAH T4 NSCLC (Stage 3B or worse) Variable HR (95% CI) Systolic Blood Pressure ≤ 113 mmHg 2.6 (1.7

  82. Slide 82: NYHA Functional Class: Symptom Rating Scale

    NYHA Functional Class: Symptom Rating Scale   Class 1   Class 4    Class 3   Class 2

  83. Slide 83: Large Unmet Need: No Treatment for Most Group 2 PH

    Large Unmet Need: Most Group 2 PH from HFpEF and there is NO Medical/Surgical Treatment Mitral Valve Disease MVD (~46%)     HighLow Heart Failure Reduced Ejection Fraction HFrEF (~15%)   HighLow   Heart Failure Preserved Ejection Fraction HFpEF (~39%)     No surgical or medical solution

  84. Slide 84: Recent Randomized Controlled Trials in PH Due to LHD

    Recent Randomized Controlled Trials Targeting PDE5/NO and ET Pathways in PH Due to LHD First Author or Study Study Drug Dose Subjects n Duration Population Primary Outcome Result Guazzi1 Sildenafil 50 mg, t.i.d. 44 12 months HFpEF PVR, RV performance, CPET Improvement LEPHT2 Riociguat 0.5, 1 or 2 mg

  85. Slide 85: Limitations/Challenges of PAH-Approved Vasodilation Treatment

    Limitations/Challenges PAH-Approved Vasodilation Treatment

  86. Slide 86: Current Treatments for Group 2 PH Patients are Limited

    Treatment Options Rare Heart Transplantation or Supportive Care PAH-Approved Treatment Use in Select Patients Treat Underlying Left Heart Disease Lifestyle Interventions to Mitigate PH Evaluate for Pharmacotherapy Emerging Therapies Current Treatments for Group 2 PH Patients are Limited with No Appr

  87. Slide 87: ESC/ERS Guidelines

    ESC/ERS Guidelines Use of PAH-approved therapies is NOT recommended (currently approved)

  88. Slide 88: Scientific Rationale and Preclinical Research in WHO Group 2 PH

    Patrick Andre, PhD Head of Biology, Acceleron S C IEN TI F IC R ATI ON AL E AN D P R EC L IN IC A L R ES EAR C H IN W H O GR OU P 2 PH

  89. Slide 89: Group 2 PH: Development and Similarities with PAH

    Group 2 PH – Development & Similarities with PAH Gp2 PH: Represents a sub-phenotype of PH-LHD that shares physiological and molecular (hemodynamic & genetic) similarities with PAH: Systolic/Diastolic PA pressure; mPaP, PVR; Gene-ontology J Am Coll Cardiol 2016; 68: 2525-2536. Doi:10.1016/j.jacc.2016

  90. Slide 90: PAH and Group 2 PH Similarities: Activin A Levels

    PAH – Group 2 PH Similarities: Activin A Levels are Associated with Disease Severity • Human Genetics and Pharmacological Evidence involving the Activin Pathway • Mice

  91. Slide 91: Activin A as a Key Driver of the Disease

    PAH – Group 2 PH Similarities: Activin A as a Key Driver of the Disease • Mice Genetics and Pharmacological Evidence involving the Activin Pathway

  92. Slide 92: ZSF1 Obese Rat Model of HFpEF-PH

    ZSF1 Obese Rat Model Recapitulates Key Pathological Features of HFpEF-PH • • • M. Ob. F. Ob. PLOS ONE | https://doi.org/10.1371/ journal.pone.0232399 E/ e’

  93. Slide 93: RAP-011 Aim & Approach

    RAP-011 Vehicle Aim & Approach Aim • Obese ZSF1 Rat Approach SU5416 Echo Fasting glucose • Echo • Hemodynamics • GTT Histology

  94. Slide 94: RAP-011 Improves Diastolic Function in HFpEF-PH Model

    Results: RAP-011 Improves Diastolic Function, Reduces Left Heart Remodeling in Sugen/ZSF1 - HFpEF-PH Model Reduced Stiffness p<0.05 p<0.01 p<0.0001. E/E’: LVM:

  95. Slide 95: RAP-011 Reduces RVSP, Improves RV Function

    Results: RAP-011 Reduces RVSP, Improves RV Function in ZSF1 HFpEF-PH Model Am J Respir Crit Care Med 2021;203;A3649 Wk 22 p<0.05 p<0.01. RVSP: RVFWT

  96. Slide 96: Summary

    Summary Preclinical pharmacological evaluation in HFpEF model of left heart disease: • • • Consistent results in additional preclinical models: • • Findings support clinical evaluation of sotatercept in patients with Group 2 PH Protective effects observed at “PAH-effective doses” •

  97. Slide 97: Phase 2 Study of Sotatercept in CpcPH (HFpEF, WHO Group 2 PH)

    Mardi Gomberg-Maitland, MD, MSc* Professor of Medicine and Director of the Pulmonary Hypertension Program at The George Washington University Hospital A Phase 2, double blind, randomized, placebo- controlled, parallel-group study of sotatercept in patients with combined pre- and post-capillary pulmo

  98. Slide 98: Patient Case Presentation

    Patient Case Presentation   NYHA Class III   NTproBNP was elevated at 7,000 ug/ml,

  99. Slide 99: Patient Case Presentation: ECHO

    Patient Case Presentation: ECHO

  100. Slide 100: Patient Case Presentation: Hemodynamics

    Patient Case Presentation: Hemodynamics  Her RHC demonstrated CpcPH  Elevated right heart, pulmonary, and left heart pressures with an elevated pulmonary vascular resistance  She was admitted for optimization with planned outpatient screening for the CADENCE trial PA 70/28/42 PCWP 18 PVR 4.8

  101. Slide 101: CADENCE Phase 2 Trial Inclusion Criteria

    CADENCE Phase 2 Trial Inclusion Criteria Key Inclusion Criteria • NYHA functional class II or III • Baseline right heart catheterization with Pulmonary vascular resistance ≥4 Wood units, Mean pulmonary arterial pressure >25, Pulmonary capillary wedge pressure >15 and <30 • 6-minute walk distance ≥10

  102. Slide 102: CADENCE Phase 2 Trial Design Schema

    CADENCE Phase 2 Trial Design Schema Randomization 1:1:1 (24 weeks) Placebo Sotatercept 0.3mg/kg (18 months) (4 weeks) Sotatercept 0.3 mg/kg Sotatercept 0.3 mg/kg Sotatercept 0.3mg/kg to 0.7 mg/kg after 3rd cycle Primary Endpoint Analysis

  103. Slide 103: CADENCE 24-week Endpoints

    CADENCE 24-week Endpoints Primary Endpoint • Change in pulmonary vascular resistance from baseline to week 24 Key Secondary Endpoint • Change in 6-minute walk distance from baseline to week 24

  104. Slide 104: CADENCE Additional Endpoints

    CADENCE Additional Endpoints • Clinical Worsening Events: Number of Clinical Worsening event, time to Clinical Worsening and number of participants with first Clinical Worsening event were measured. - Number of Clinical Worsening Events at 24 weeks and 48 weeks. - Number of participants with first C

  105. Slide 105: Jay Backstrom, Head of Research & Development

    J AY B AC KS TR OM , MD , M PH H E A D O F R E S E A R C H & D E V E L O P M E N T

  106. Slide 106: Sotatercept Development in Pulmonary Hypertension

    Sotatercept Development in Pulmonary Hypertension GROUP 1 Pulmonary Arterial Hypertension GROUP 2 Left Heart Disease GROUP 3 Interstitial Lung Disease TBD WHO PH Group Scientific and Preclinical Evaluation Ongoing ZENITH

  107. Slide 107: Sotatercept & Pulmonary Hypertension Focused Q&A Session

    Sotatercept & Pulmonary Hypertension Focused Q&A Session M A R C H U M B E R T , M D , P H D * V A L L E R I E M C L A U G H L I N , M D * M A R D I G O M B E R G , M D , M S c * H A B I B D A B L E J A Y B A C K S T R O M , M D , M P H J A N E T H E P E N A , M D , P H D P A T R I C K A N D R E , P

  108. Slide 108: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

    Janethe Pena, MD, PhD Head of Pulmonary Medical Research, Acceleron S Y S TEM IC S C L ERO SI S- A SS OC I AT ED IN TER S TI TI AL L U NG D IS EAS E (S SC - IL D )

  109. Slide 109: Scleroderma/Systemic Sclerosis

    Scleroderma/Systemic Sclerosis Scleroderma Localized Scleroderma Systemic Sclerosis (Systemic Scleroderma) Morphea Linear Sclerosis Limited Cutaneous Systemic Sclerosis Diffuse Cutaneous Systemic Sclerosis Systemic Sclerosis Sine Scleroderma

  110. Slide 110: Classification of Systemic Sclerosis

    Classification of Systemic Sclerosis

  111. Slide 111: Common Manifestations of Systemic Sclerosis

    Common Manifestations of Systemic Sclerosis Skin Gastrointestinal Musculoskeletal Hands Heart Kidney Lungs TGF-b Linked

  112. Slide 112: Overview of SSc-ILD

    Overview of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Healthy Lung SSc-ILD Lung • Driven by a combination of autoimmunity, fibrosis, inflammation, and vascular injury • Fibrotic scarring of the alveolar wall impedes oxygen transportation and eventual replaces normal pulmonary

  113. Slide 113: SSc-ILD US/EU Prevalence

    SSc-ILD US/EU Prevalence >50K PATIENTS

  114. Slide 114: Common Symptoms in Systemic Sclerosis Patients with ILD

    Common Symptoms in Systemic Sclerosis Patients with ILD Cough Chest PainDizziness and/or Fainting Exertion Fatigue

  115. Slide 115: ILD is the Leading Cause of Death in Systemic Sclerosis

    ILD is the Leading Cause of Death in Patients with Systemic Sclerosis (SSc) 5-year and 10-year Survival Rates by SSc Classification* SSc-related Death and Organ System Involvement* Source: Semin Arthritis Rheum

  116. Slide 116: Treatment Algorithm for SSc-ILD Patients

    Treatment Algorithm for SSc-ILD Patients Immunosuppressive therapy nintedanib tocilizumab Additional options (Multiple unapproved agents) HSCT or Lung Transplant

  117. Slide 117: Unmet Need for Patients with SSc-ILD

       Unmet Need for Patients with SSc-ILD

  118. Slide 118: Scientific Rationale and Preclinical Research in SSc-ILD

    Patrick Andre, PhD Head of Biology, Acceleron S C IEN TI F IC R ATI ON AL E AN D P R EC L IN IC A L R ES EAR C H IN S SC - IL D

  119. Slide 119: Fibrosis is the Hallmark of SSc & SSc-ILD

    Fibrosis is the Hallmark of SSc & SSc-ILD SSc-ILD Lungs Oesophagus Heart Kidney Thickened Skin Intestine Raynaud’s TGF-b1 Dantas AT, et al (2016) Dis Markers. Circulating TGF-β1 level is increased in SScTGF-b1

  120. Slide 120: TGF-β-mediated Fibrosis in SSc-ILD

    TGF-β-mediated Fibrosis in ILD (SSc) Transcription (TGF-b, Col1A1, a-SMA…) TGF-b

  121. Slide 121: ACE-1334, RAP-1332: Specific Ligand Traps for TGF-β

    ACE-1334, RAP-1332: Specific Ligand Traps for TGF-β 1, 3 • ACE-1334 is a homodimeric Fc fusion protein comprised of the extracellular domain of the human TGF-b receptor type II (TGFβRII), linked to a human IgG1 Fc domain • ACE-1334 binds with high affinity to TGF-β1 and TGF-β3 • RAP-1332 is a homodi

  122. Slide 122: The Systemic Bleomycin Mouse Model of SSc-ILD

    The Systemic Bleomycin (mini-pump) Mouse Model of SSc-ILD     

  123. Slide 123: SSc-ILD Model Evaluation

    SSc-ILD Model Evaluation Bleomycin Minipump Treatment Biw, s.c. ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱ Target Engagement

  124. Slide 124: Effect of RAP-1332 on Markers of Pulmonary Fibrosis

    Effect of RAP-1332 on Markers of Pulmonary Fibrosis Col1a1 mRNA

  125. Slide 125: The Fra-2 Translational Model of SSc-ILD

    The Fra-2 (Fos-related antigen-2) Translational Model of SSc-ILD    https://doi.org/10.1016/j.cellsig.2019.109408 Lung Skin F. Fra-2 Fra-2 Fra-2 Tg (Fra-2)WT Eferl R, et al (2008) Proc Natl Acad Sci USA

  126. Slide 126: RAP-1332 Reduces Lung Fibrosis in Fra-2 Tg Model

    RAP-1332 Reduces Lung Fibrosis in Fra-2 Tg SSc-ILD Model WT Fra 2 tg w k8 Fra 2 tg /Sa line Fra 2 tg /13 32 0 10 20 30 40 ** # *** Fra2Tg +PBS Fra2Tg +1332 Fra2Tg 8wks WT

  127. Slide 127: RAP-1332 Shows a Trend in Reduced Inflammation in Lungs

    RAP-1332 Shows a Trend in Reduced Inflammation in Lungs from Fra-2 Tg Mice WT 8 WK Control FRA2 8 WK FRA2 16 WK PBS FRA2 16 WK RAP-1332 CNIO-FRA2 IHC F4/80 Positive cells (%)

  128. Slide 128: RAP-1332 Summary in SSc-ILD Models

    RAP-1332 (ACE-1334 analog) Summary in SSc-ILD Models • • • • •

  129. Slide 129: ACE-1334 Clinical Development Plan in SSc-ILD

    AC E-1 33 4 C L I NI C AL D EVEL OP MEN T PL A N IN SS C - IL D Janethe Pena, MD, PhD Head of Pulmonary Medical Research, Acceleron

  130. Slide 130: ACE-1334 in Systemic Sclerosis

    ACE-1334 in Systemic Sclerosis ACE-1334 FAST TRACK DESIGNATION ORPHAN DRUG DESIGNATION

  131. Slide 131: ACE-1334 Phase 1 Study Takeaways

    ACE-1334 Phase 1 Study Takeaways • Single-ascending dose design • Healthy volunteer subjects • ACE-1334 was generally well tolerated • Strong relationship between dose and pharmacokinetic / pharmacodynamic markers ACE-1334 P H A S E 1

  132. Slide 132: ACE-1334 Phase 1b Study Inclusion Criteria

    ACE-1334 Phase 1b Study Inclusion Criteria Inclusion Criteria • Diffuse systemic sclerosis • Modified Rodnan skin score ≥15 • Forced vital capacity ≥50% predicted • Elevated acute phase reactants • Disease duration ≤60 months • Diffusing capacity of the lungs for carbon monoxide ≥40% - ≤89% • Stable

  133. Slide 133: ACE-1334 Phase 1b Study Design

    ACE-1334 Phase 1b Study Design Open-label treatment period Randomization 1:1 ACE-1334 dose 2 (mg/kg) Q4W + SOC ACE-1334 dose 1 (mg/kg) Q2W + SOC Go to Phase 2 ACE-1334 dose 4 (mg/kg) Q4W + SOC ACE-1334 dose 3 (mg/kg) Q2W + SOC ACE-1334 dose 6 (mg/kg) Q4W + SOC ACE-1334 dose 5 (mg/kg) Q2W + SOC Conti

  134. Slide 134: ACE-1334 Phase 1b Biomarkers and Quantitative Systems Pharmacology

    ACE-1334 Phase 1b Study – Biomarkers and Quantitative Systems Pharmacology Dose-response modeling and evaluation Dose Identification

  135. Slide 135: Phase 2 Trial Design

    Phase 2 Trial Design • Dose to be informed by Phase 1b results • Phase 2 will be a randomized, double-blind, placebo- controlled trial design with two ACE-1334 dose arms versus standard of care. • Patient population: systemic sclerosis associated interstitial lung disease • Primary endpoint: forced

  136. Slide 136: Closing Remarks

    J AY B AC KS TR OM , MD , M PH H E A D O F R E S E A R C H & D E V E L O P M E N T C L O S I N G R E M A R K S

  137. Slide 137: R&D Day Highlights/Key Takeaways

        R&D Day Highlights/Key Takeaways

  138. Slide 138: Closing Q&A Session

    Closing Q&A Session H A B I B D A B L E J A Y B A C K S T R O M , M D , M P H J A N E T H E P E N A , M D , P H D P A T R I C K A N D R E , P H D S U J A Y K A N G O R A V I K U M A R , P H D

  139. Slide 139: Thank You

    TH A NK YOU ! F O R M O R E I N F O R M A T I O N , P L E A S E V I S I T O U R N E W W E B S I T E

Acceleron Pharma — Investor Day (June 2021) on 6ix